Literature DB >> 8335500

Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats.

T Mindermann1, H Landolt, W Zimmerli, Z Rajacic, O Gratzl.   

Abstract

Rifampicin is used to treat neurosurgical shunt infections because of its excellent in-vitro activity against staphylococci and its adequate penetration into the CSF. However, nothing is known about rifampicin concentrations in the cerebral extra-cellular space (CES). We measured the penetration of rifampicin into the CES of anaesthetized rats by microdialysis using low-flow and equilibrium methods. Depending on the method, rifampicin concentrations in the CES were 0.3-1% of the serum concentration or 3-8% of brain tissue concentration, respectively. These experimental data in animals suggest that the recommended dose of rifampicin in man might be inadequate for treatment of some brain infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335500     DOI: 10.1093/jac/31.5.731

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Christina Patrick; Anthony Adame; Monica Thukral; Clifford Shults; Eliezer Masliah
Journal:  Neuroreport       Date:  2008-08-27       Impact factor: 1.837

3.  Effects of intraocular rifampicin on retinal ganglion cell structure: a stereological and histopathological study.

Authors:  Ozgür Cakici; Selina Aksak; Deniz Unal; Sare Sipal; Sadullah Keles; Talha Dumlu; Murat Karamese
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

Review 4.  Application of microdialysis in pharmacokinetic studies.

Authors:  W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

5.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern
Journal:  Lancet Neurol       Date:  2014-02-05       Impact factor: 44.182

6.  Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.

Authors:  Li Liu; Youwen Xu; Colleen Shea; Joanna S Fowler; Jacob M Hooker; Peter J Tonge
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 7.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Analysis of ceftriaxone and ceftazidime distribution in cerebrospinal fluid of and cerebral extracellular space in awake rats by in vivo microdialysis.

Authors:  L Granero; M Santiago; J Cano; A Machado; J E Peris
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.

Authors:  Xiaohui Wang; Peter M Grace; Michael N Pham; Kui Cheng; Keith A Strand; Christina Smith; Jing Li; Linda R Watkins; Hang Yin
Journal:  FASEB J       Date:  2013-04-08       Impact factor: 5.191

10.  Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space.

Authors:  T Mindermann; W Zimmerli; O Gratzl
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.